Precipio, Inc. (NASDAQ:PRPO) Short Interest Update

Precipio, Inc. (NASDAQ:PRPO) was the recipient of a large decline in short interest during the month of January. As of January 15th, there was short interest totaling 3,304 shares, a decline of 33.8% from the December 31st total of 4,991 shares. Based on an average daily trading volume, of 8,064 shares, the short-interest ratio is currently 0.4 days. Approximately 0.2% of the company’s shares are sold short. Approximately 0.2% of the company’s shares are sold short. Based on an average daily trading volume, of 8,064 shares, the short-interest ratio is currently 0.4 days.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on PRPO. Wall Street Zen lowered shares of Precipio from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Precipio in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Precipio Stock Up 1.2%

Shares of NASDAQ PRPO traded up $0.28 during trading on Friday, hitting $24.54. The stock had a trading volume of 6,579 shares, compared to its average volume of 9,233. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.27 and a quick ratio of 1.10. The firm has a fifty day moving average of $23.99 and a two-hundred day moving average of $19.90. Precipio has a 12 month low of $3.90 and a 12 month high of $28.50. The company has a market capitalization of $42.95 million, a PE ratio of -29.93 and a beta of 1.12.

Precipio (NASDAQ:PRPO) last posted its quarterly earnings data on Friday, November 14th. The biotechnology company reported ($0.05) EPS for the quarter. The firm had revenue of $6.77 million during the quarter. Precipio had a negative net margin of 5.50% and a negative return on equity of 10.07%.

Institutional Investors Weigh In On Precipio

Several large investors have recently made changes to their positions in PRPO. Susquehanna International Group LLP bought a new stake in shares of Precipio during the 3rd quarter worth $194,000. Evernest Financial Advisors LLC purchased a new stake in Precipio during the third quarter worth about $374,000. Topline Capital Management LLC bought a new stake in Precipio in the third quarter worth about $1,158,000. Finally, AMH Equity Ltd raised its holdings in shares of Precipio by 370.1% in the 3rd quarter. AMH Equity Ltd now owns 131,100 shares of the biotechnology company’s stock worth $2,332,000 after purchasing an additional 103,210 shares during the period. 10.45% of the stock is owned by hedge funds and other institutional investors.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.